Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUSP22 | Q9NRW4 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | JAK3 | P52333 | 10/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.38 |
| ▸ | JAK1 | P23458 | 2/20 | 0.37 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.37 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.37 |
| ▸ | F2R | P25116 | 1/20 | 0.37 |
| ▸ | BTK | Q06187 | 2/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21097023 | 1.00 | DUSP22 (0.40) | DUSP22KMT2AMEN1POLBJAK3 | |
| SCHEMBL21097015 | 0.91 | LMNA (0.46) | KMT2APOLBJAK3LMNAACKR3 | |
| SCHEMBL21097025 | 0.85 | ITGB3 (0.34) | DUSP22KMT2AMEN1JAK3ACKR3 | |
| SCHEMBL2757960 | 0.82 | MAPK8 (0.43) | DUSP22KMT2AMEN1POLBLMNA | |
| SCHEMBL16095734 | 0.82 | LMNA (0.45) | DUSP22KMT2AMEN1POLBLMNA | |
| SCHEMBL21097026 | 0.82 | KMT2A (0.51) | KMT2AMEN1POLBJAK3LMNA | |
| SCHEMBL2757957 | 0.81 | HPGD (0.50) | DUSP22KMT2AMEN1POLBLMNA | |
| SCHEMBL21097022 | 0.81 | BCHE (0.43) | JAK3LMNAITGB3ITGA2BF2R | |
| SCHEMBL19230457 | 0.79 | ALDH1A1 (0.41) | JAK3LMNAJAK1BTKEGFR | |
| SCHEMBL2757938 | 0.78 | MEN1 (0.48) | DUSP22KMT2AMEN1LMNAITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190185518-A9 | WARHEAD-CONTAINING PEPTIDOMIMETIC MACROCYCLES AS MODULATORS OF BFL-1 | AILERON THERAPEUTICS, INC. | 2019-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190185518-A9 | WARHEAD-CONTAINING PEPTIDOMIMETIC MACROCYCLES AS MODULATORS OF BFL-1 | BCL2L11, BCL2L1, BCL2L13 | DUSP22 1279/4885KMT2A 3692/4885MEN1 1644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.